Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. SPY
5. ACN
6. IBM
7. PFE
8. TSLA
9. DPZ
10. NVDA

Go back to Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
AGIOS PHARM (NASDAQ: AGIO) Delayed: 35.74 +0.64 (1.82%)
Previous Close $35.10    52 Week High $71.49 
Open $34.82    52 Week Low $33.50 
Day High $35.77    P/E N/A 
Day Low $34.63    EPS $-1.18 
Volume 326,190